41744-75-6

Usage

Uses

Used in Chemical Synthesis:
16-methylheptadecan-1-ol is used as a reactant/reagent for the preparation of organic compounds with linear aliphatic hydrocarbon groups. Its unique structure allows it to be a valuable component in the synthesis of various organic molecules.
Used in Industrial Processes:
In the industrial sector, 16-methylheptadecan-1-ol is used as a precipitation accelerator. Its ability to enhance the precipitation process in certain methods is beneficial for improving efficiency and reducing production time in various manufacturing processes.
Used in Pharmaceutical and Cosmetic Industries:
Due to its unique chemical structure, 16-methylheptadecan-1-ol can be employed in the development of pharmaceutical and cosmetic products. Its properties may contribute to the formulation of creams, lotions, and other personal care products, as well as potentially serving as a component in drug delivery systems.
Used in Research and Development:
The unique structure and properties of 16-methylheptadecan-1-ol make it an interesting compound for research and development purposes. Scientists and researchers can explore its potential applications in various fields, including material science, drug discovery, and chemical engineering.

InChI:InChI=1/C18H38O/c1-18(2)16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19/h18-19H,3-17H2,1-2H3

Upstream product

• 2724-58-5 16-methylheptadecanoic acid 
• 179108-70-4 16-methyl-1-(2-tetrahydropyranyloxy)heptadecane 
• 5129-61-3 methyl isostearate 
• 5963-14-4 8-methylnonanoic acid 
• 818-88-2 sebacic acid mono methyl ester 
• 179108-69-1 1-hydroxy-15-iodopentadecane 
• 179108-67-9 2-(15-iodopentadecyl)oxytetrahydro-2-hydro-pyran 

Downstream Products

• 2724-58-5 16-methylheptadecanoic acid 
• 2724-59-6 17-methyloctadecanoic acid 

Relevant academic research and scientific papers

Curable inks comprising diurethane gelators

The disclosure provides curable inks including a diurethane gelator having the structure of Formula I. wherein R and R′ each, independently of the other, is a C1-C22 saturated aliphatic hydrocarbon group selected from the group consisting of (1) linear aliphatic groups, (2) branched aliphatic groups, (3) cyclic aliphatic groups, (4) aliphatic groups containing both cyclic and acyclic portions, any carbon atom of the saturated aliphatic hydrocarbon group may be optionally substituted with an alkyl group (cyclic or acyclic), wherein (1) and (2) groups have a carbon number of from about 1 to about 22 carbons, and wherein (3) and (4) groups have a carbon number of from about 4 to about 10 carbons; and X is selected from the group consisting of: (i) an alkylene group, (ii) an arylene group, (iii) an arylalkylene group, and (iv) an alkylarylene group.

A practical synthesis of long-chain iso-fatty acids (iso-C 12-C19) and related natural products

A gram-scale synthesis of terminally-branched iso-fatty acids (iso-C 12-C19) was developed commencing with methyl undec-10-enoate (methyl undecylenate) (for iso-C12-C14) or the C15 and C16 lactones pentadecanolide (for iso-C 15-C17) and hexadecanolide (for iso-C18-C 19). Central to the approaches outlined is the two-step construction of the terminal isopropyl group through addition of methylmagnesium bromide to the ester/lactones and selective reduction of the resulting tertiary alcohols. Thus, the C12, C17 and C18 iso-fatty acids were obtained in three steps from commercially-available starting materials, and the remaining C13-C16 and C19 iso-fatty acids were prepared by homologation or recursive dehomologations of these fatty acids or through intercepting appropriate intermediates. Highlighting the synthetic potential of the iso-fatty acids and various intermediates prepared herein, we describe the synthesis of the natural products (S)-2,15-dimethylpalmitic acid, (S)-2-hydroxy-15-methylpalmitic acid, and 2-oxo-14-methylpentadecane.

Growth Hormone Secretagogue Receptor 1A Ligands

The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

Dilithium tetrachlorocuprate catalyzed alkylation of aleuritic acid derivatives and synthesis of muscalure

Carbon-carbon coupling with the ω-halo or tosyl derivatives of threo-9,10,16-trihydroxyhexadecanoic acid (aleuritic acid) has been carried out in the presence of dilithium tetrachlorocuprate reagent and a short synthesis of muscalure is reported.

Pharmaceutical compositions and methods for treatment and prophylaxis of cancer

A pharmaceutical composition comprising, in admixture with a pharmacologically acceptable carrier, an isomonool of the formula STR1 wherein R is an alkyl group with 1 to 5 carbon atoms, and n is an integer of 4 to 22, have carcinostatic, carcinostasis-reinforcing and carcinogenesis-preventing activity.

α-Mono (methyl-branched alkyl) glyceryl ether and a skin care cosmetic composition containing the same

α-mono(methyl-branched alkyl) glyceryl ethers represented by the formula STR1 where m is an integer of 2 to 14, n is an integer of 3 to 11, and the total of m+n is 11 to 17, are disclosed along with skin care compositions containing the same as emulsifiers.